American Lung Association Honors David F. Yankelevitz, MD, With James L. Mulshine, MD, International Leadership Award

The American Lung Association is pleased to announce that David F. Yankelevitz, MD, received the James L. Mulshine, MD, International Leadership Award at the upcoming Quantitative Imaging Workshop (QIW), held on November 12 and 13. The award recognizes individuals who have had a profound impact on reducing the toll of lung cancer, chronic obstructive pulmonary disease (COPD) and cardiovascular disease.

Dr. Yankelevitz is a Professor of Radiology and the Director of Lung Biopsy Service at the Icahn School of Medicine at Mount Sinai in New York. He is a world-recognized expert on Fine-Needle Aspiration (FNA) of lung nodules, which is a key part of the lung cancer diagnostic process. Dr. Yankelevitz’s research focuses on the evaluation of treatments for early-diagnosed lung cancer. He has co-authored more than 300 peer-reviewed articles and book chapters. Most notably, he has served as the co-principal investigator of the Initiative for Early Lung Cancer Research on Treatment (IELCART) since its inception in 2015.

“We are pleased to recognize Dr. Yankelevitz with the James L. Mulshine, MD, International Leadership Award for his in volumetric assessment of lung nodule growth,” said Harold Wimmer, President and CEO of the Lung Association. “In partnership with Dr. Claudia Henschke, Dr. Yankelevitz developed and sustained the lung cancer screening collaborative mechanism known as the International Early Lung Cancer Action Project. Over the past 25 years, this consortium has published more than 400 publications advancing the progress in detecting and curing early lung cancer across the world.”

The Quantitative Imaging Workshop, hosted by the American Lung Association this year, is largely virtual with moderators convening in-person for it at the Lung Association’s headquarters in Chicago. The event, now in its 22nd year, brings together experts from around the world for the advancement of quantitative low-dose computed tomography (LDCT) imaging biomarkers for detection and management of early thoracic disease—lung cancer, COPD and cardiovascular disease—which are conditions that rank among the leading causes of death in the U.S.

This is the Lung Association’s first year as the lead organization of the Quantitative Imaging Workshop, after several years of serving as a key partner. The workshop brings together two of the Lung Association’s strategic imperatives—defeating lung cancer and improving the quality of life for those living with lung disease and their families—and will help the organization sustain the research infrastructure necessary to move scientific findings toward meaningful public health impact. The effort is part of the American Lung Association Research Institute, which addresses critical lung health challenges by investing in lung disease research, expanding industry collaboration and empowering promising scientists to accelerate discovery and innovation.

For more information on the Quantitative Imaging Workshop, visit: www.qiworkshop.com.